Another Strong Quarter For AbbVie, But How Long Will Good Times Last?

With continued strong growth for Humira, AbbVie doubles down on confidence to protect the franchise with IP strategy. Imbruvica and Viekira Pak show growth, although the latter is flourishing only ex-US.

The narrative on AbbVie Inc. has been unchanging – it relies too much on top-seller Humira, is clearly behind Gilead in hepatitis C and its cancer portfolio and pipeline, while promising, aren't threatening to overtake competitors like Bristol-Myers Squibb Co. or Merck & Co. Inc. To that familiar litany, AbbVie continued its recent success July 29, reporting a sixth consecutive quarter of double-digit sales growth, paced by continued increasing sales of Humira.

The Chicago-area pharma brought in $6.432bn in global net revenue during the second quarter of 2016, up 18.0% year-over-year, with...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category